83 related articles for article (PubMed ID: 26852170)
21. Role of first-line anti-epidermal growth factor receptor therapy compared with anti-vascular endothelial growth factor therapy in advanced colorectal cancer: a meta-analysis of randomized clinical trials.
Khattak MA; Martin H; Davidson A; Phillips M
Clin Colorectal Cancer; 2015 Jun; 14(2):81-90. PubMed ID: 25666296
[TBL] [Abstract][Full Text] [Related]
22. Is There a Survival Benefit of First-Line Epidermal Growth Factor Receptor Tyrosine-Kinase Inhibitor Monotherapy Versus Chemotherapy in Patients with Advanced Non-Small-Cell Lung Cancer?: A Meta-Analysis.
Guetz GD; Landre T; Uzzan B; Chouahnia K; Nicolas P; Morere JF
Target Oncol; 2016 Feb; 11(1):41-7. PubMed ID: 26092590
[TBL] [Abstract][Full Text] [Related]
23. Meta-analysis of molecular targetted agents in the treatment of elderly patients with metastatic colorectal cancer: does the age matter?
Zhao C; Li S; Liu Q
J Chemother; 2016 Aug; 28(4):321-7. PubMed ID: 26239366
[TBL] [Abstract][Full Text] [Related]
24. Erlotinib-based targeted dual agent versus erlotinib alone in previously treated advanced non-small-cell lung cancer: a meta-analysis of 13 randomized controlled trials.
Yu S; Xu Q; Yuan Y; Li X; Cai H
Curr Med Res Opin; 2016 Dec; 32(12):1927-1934. PubMed ID: 27479336
[TBL] [Abstract][Full Text] [Related]
25. Does the Chemotherapy Backbone Impact on the Efficacy of Targeted Agents in Metastatic Colorectal Cancer? A Systematic Review and Meta-Analysis of the Literature.
Chan DL; Pavlakis N; Shapiro J; Price TJ; Karapetis CS; Tebbutt NC; Segelov E
PLoS One; 2015; 10(8):e0135599. PubMed ID: 26275292
[TBL] [Abstract][Full Text] [Related]
26. Systematic Review of the Role of Targeted Therapy in Metastatic Neuroendocrine Tumors.
Lee A; Chan DL; Wong MH; Li BT; Lumba S; Clarke SJ; Samra J; Pavlakis N
Neuroendocrinology; 2017; 104(3):209-222. PubMed ID: 27082107
[TBL] [Abstract][Full Text] [Related]
27. C-reactive protein is a predictor of prognosis in renal cell carcinoma patients receiving tyrosine kinase inhibitors: A meta-analysis.
Wang Z; Peng S; Wang A; Xie H; Guo L; Jiang N; Niu Y
Clin Chim Acta; 2017 Dec; 475():178-187. PubMed ID: 29080691
[TBL] [Abstract][Full Text] [Related]
28. The Efficacy of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer Harboring Wild-type Epidermal Growth Factor Receptor: A Meta-analysis of 25 RCTs.
Sheng Z; Zhang Y
Am J Clin Oncol; 2017 Aug; 40(4):362-369. PubMed ID: 25647830
[TBL] [Abstract][Full Text] [Related]
29. Efficacy and Safety of Combined Androgen Deprivation Therapy (ADT) and Docetaxel Compared with ADT Alone for Metastatic Hormone-Naive Prostate Cancer: A Systematic Review and Meta-Analysis.
Botrel TE; Clark O; Lima Pompeo AC; Horta Bretas FF; Sadi MV; Ferreira U; Borges Dos Reis R
PLoS One; 2016; 11(6):e0157660. PubMed ID: 27308831
[TBL] [Abstract][Full Text] [Related]
30. Genomic sequencing to inform therapy in advanced pancreatic cancer: A systematic review and meta-analysis of prospective studies.
Meti N; Kelly D; Allen MJ; Lanys A; Fazelzad R; Ramjeesingh R; Zogopoulos G; Notta F; Knox JJ; Amir E; Gallinger S; O'Kane G; Grant RC
Cancer Treat Rev; 2021 Dec; 101():102310. PubMed ID: 34757307
[TBL] [Abstract][Full Text] [Related]
31. New molecular therapies in patients with advanced Hepatocellular Cancer in second line of treatment: Is a real defeat?: Results from a literature based meta-analysis of randomized trials.
Roviello G; Zanotti L; Cappelletti MR; Gobbi A; Borsella G; Pacifico C; Multari AG; Generali D
Crit Rev Oncol Hematol; 2016 Dec; 108():62-68. PubMed ID: 27931841
[TBL] [Abstract][Full Text] [Related]
32. Effect of Body Mass Index on Overall Survival of Pancreatic Cancer: A Meta-Analysis.
Shi YQ; Yang J; Du P; Xu T; Zhuang XH; Shen JQ; Xu CF
Medicine (Baltimore); 2016 Apr; 95(14):e3305. PubMed ID: 27057903
[TBL] [Abstract][Full Text] [Related]
33. miRNA Predictors of Pancreatic Cancer Chemotherapeutic Response: A Systematic Review and Meta-Analysis.
Madurantakam Royam M; Ramesh R; Shanker R; Sabarimurugan S; Kumarasamy C; Ramesh N; Gothandam KM; Baxi S; Gupta A; Krishnan S; Jayaraj R
Cancers (Basel); 2019 Jun; 11(7):. PubMed ID: 31252688
[TBL] [Abstract][Full Text] [Related]
34. Metformin and pancreatic cancer survival: Real effect or immortal time bias?
Wei M; Liu Y; Bi Y; Zhang ZJ
Int J Cancer; 2019 Oct; 145(7):1822-1828. PubMed ID: 30848544
[TBL] [Abstract][Full Text] [Related]
35. Defining new paradigms for the treatment of pancreatic cancer.
Almhanna K; Philip PA
Curr Treat Options Oncol; 2011 Jun; 12(2):111-25. PubMed ID: 21461670
[TBL] [Abstract][Full Text] [Related]
36. Targeted therapies for pancreatic cancer.
Danovi SA; Wong HH; Lemoine NR
Br Med Bull; 2008; 87():97-130. PubMed ID: 18753179
[TBL] [Abstract][Full Text] [Related]
37. Targeted Approach Succeeds in Pancreatic Cancer.
Cancer Discov; 2020 Jun; 10(6):753. PubMed ID: 32273294
[TBL] [Abstract][Full Text] [Related]
38. Current therapeutic strategies for advanced pancreatic cancer: A review for clinicians.
Spadi R; Brusa F; Ponzetti A; Chiappino I; Birocco N; Ciuffreda L; Satolli MA
World J Clin Oncol; 2016 Feb; 7(1):27-43. PubMed ID: 26862489
[TBL] [Abstract][Full Text] [Related]
39. Establishment and Molecular Characterization of Two Patient-Derived Pancreatic Ductal Adenocarcinoma Cell Lines as Preclinical Models for Treatment Response.
Braun R; Lapshyna O; Watzelt J; Drenckhan M; Künstner A; Färber B; Hael AAM; Bolm L; Honselmann KC; Konukiewitz B; Castven D; Spielmann M; Gorantla SP; Busch H; Marquardt JU; Keck T; Wellner UF; Ungefroren H
Cells; 2023 Feb; 12(4):. PubMed ID: 36831254
[TBL] [Abstract][Full Text] [Related]
40. Epigenetic regulation of pancreatic adenocarcinoma in the era of cancer immunotherapy.
Kawakubo K; Castillo CF; Liss AS
J Gastroenterol; 2022 Nov; 57(11):819-826. PubMed ID: 36048239
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
